Anyone who has suffered through a urinary tract infection knows the drill: visit the doctor, provide a sample, get prescribed a broad-spectrum antibiotic, and hope it works while waiting two to three days for lab results to confirm which drug is actually effective. For millions of patients each year, that wait means unnecessary suffering — and sometimes dangerous complications.
That wait may soon be a thing of the past. Researchers at the University of Reading, working with the University of Southampton and Hampshire Hospitals NHS Foundation Trust, have developed a rapid test that identifies the right antibiotic for a UTI in an average of just 5.85 hours. The results, published March 31 in the Journal of Antimicrobial Chemotherapy, matched standard laboratory methods in 96.95% of cases across seven first-line antibiotics.
How It Works
The breakthrough lies in eliminating the overnight culturing step that has been the bottleneck in UTI diagnosis for decades. In traditional testing, urine samples must be incubated so bacteria can multiply to detectable levels — a process that adds one to two full days before antibiotic sensitivity testing can even begin.
The new method skips this entirely. A cartridge containing small tubes preloaded with different antibiotics is placed directly into the urine sample and inserted into an instrument. The system then uses optical imaging to monitor bacterial growth in each tube. If bacteria stop growing in a particular tube, the antibiotic in that tube works. If growth continues, it doesn't. The answer arrives the same day.
The Stakes Are High
UTIs are among the most common bacterial infections worldwide. In England alone, they have caused more than 800,000 hospital admissions over the past five years. About one in four urine samples tested in NHS laboratories contains bacteria resistant to commonly prescribed antibiotics — meaning many patients receive ineffective treatment on their first try.
The consequences of delayed or incorrect treatment extend beyond discomfort. Untreated or poorly treated UTIs can progress to kidney infections and potentially life-threatening sepsis. Each unnecessary prescription of a broad-spectrum antibiotic also contributes to the growing crisis of antimicrobial resistance, which the World Health Organization has called one of the greatest threats to global health.
From Lab to Clinic
A second analysis of 90 duplicate samples showed 98.75% agreement between preserved and fresh samples, confirming the test remains accurate even when samples need to be transported or stored before analysis.
Astratus Limited, a University of Reading spin-out company, will bring the technology to market. "Being able to tell a doctor the same day which antibiotic to use means the patient gets the right treatment sooner, reducing the risk of resistance developing and their infection turning into potentially lethal sepsis," said Dr. Oliver Hancox, the company's CEO.
With approximately 65 million urine samples analyzed annually in the UK alone, the potential impact is enormous. If this test reaches widespread clinical use, it could fundamentally change how one of the world's most common infections is treated — faster for patients, smarter for medicine, and better for the fight against antibiotic resistance.
